Jean-Claude Juncker
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
EMA’s PRIME scheme launches three major new features
The scheme supports the development of treatments targeting unmet medical needs in the EU
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Lilly announces plan for new $3bn facility to boost manufacturing in Europe
The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio
EU medicine shortages hit record highs in 2023 and 2024
Even with countermeasures in place, European auditors warn that the risks remain elevated
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications
J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma
The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer
Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM
The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases
Roche’s Itovebi granted EC approval to treat advanced breast cancer patients
Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases